Abstract 37P
Background
Atypical Ductal Hyperplasia (ADH) is a pre-malignant high-risk breast lesion, with morphological features similar to that of ductal carcinoma in situ (DCIS). The WHO diagnosis of ADH is defined as cytonuclear and architectural atypia <2mm in size. The current standard management is surgical excision, due to its reported 10-30% risk of upgrade to breast cancer. However, an increasingly observed alternative management utilizes a conservative approach with annual radiological follow up, quoting lower upgrade risks of 3-5%. Indications for conservative follow-up include low-risk patients or intial biopsy with vacuum assistance. Our primary aim is to investigate the ADH upgrade risk in a Singapore cohort, with a secondary goal of comparing upgrade cancer rates in upfront surgical management versus upgrade rates on conservative surveillance, to discuss feasibility of adopting a primarily conservative approach for the population.
Methods
A retrospective study was performed of 221 patients diagnosed with ADH between January 2013 to June 2023 in a tertiary institute. Initial biopsy histology, management approach and patient outcomes were evaluated. Outcome was measured by upgrade to early breast cancer. Odds ratio & relative risk was used to adjust for demographics, risk profile and biopsy methods.
Results
221 patients were diagnosed with ADH on biopsy, of whom 8 opted for surveillance. There was an overall upgrade risk of 31.22%, with 75.36% of upgrade histology being DCIS. Of all upgrades, 97.10% were diagnosed on upfront surgical excision after a mean period of 39 days, while 2.9% were diagnosed after a period of conservative surveillance. Of the 8 patients opting for conservative management, 1 patient received repeat biopsy and another 2 patients received surgical excision after a mean period of 268 days.
Conclusions
Our findings of a 31% upgrade risk of ADH to early breast cancer, consistent with that of reported literature, still support the case for upfront surgical excision of ADH. We recommend upfront surgical excision of ADH once discovered on initial biopsy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract